Previous Close | 8.74 |
Open | 8.51 |
Bid | 8.67 x 1400 |
Ask | 8.72 x 900 |
Day's Range | 8.41 - 8.84 |
52 Week Range | 6.85 - 33.10 |
Volume | |
Avg. Volume | 759,721 |
Market Cap | 353.18M |
Beta (5Y Monthly) | 1.95 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.34 |
Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.88 |
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic measures from the ongoing 6 mg dose cohort of FTX-6058 in adults with sickle cell disease (SCD) - Investor webcast to be hosted on June 10th at 8 a.m. EDT CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving th
Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
The analysts covering Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) delivered a dose of negativity to shareholders today...